Predictive Oncology appoints Dr. Veena Rao to Board; David Smith resigns

Axe Compute Inc.

David S. Smith resigned as director effective May 2, 2023, not due to any disagreement; remains advisor and outside legal counsel.
Dr. Veena Rao elected as Class III director, term expiring at 2024 annual meeting.
Rao has 25+ years in drug development, medtech, digital health; currently Chief Business Officer at Portal Instruments.
Rao will receive $5,000 in common stock as compensation for board service.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David S. Smith

Director

AGPU · Axe Compute Inc.

Effective: 2023-05-02
Successor: Veena Rao
Filed: May 2, 2023, 7:59 PM ET

On May 2, 2023, David S. Smith, JD, resigned as a director of Predictive Oncology Inc. (the “Company”), effective immediately.

Appointed

Veena Rao

Director

AGPU · Axe Compute Inc.

Effective: 2023-05-02
Filed: May 2, 2023, 7:59 PM ET

Effective May 2, 2023, the Board elected Dr. Veena Rao to the Board as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David S. Smith resigned as Director at Axe Compute Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 2, 2023, David S. Smith, JD, resigned as a director of Predictive Oncology Inc. (the “Company”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Veena Rao was elected as Director at Axe Compute Inc..

Action: elected
Role: Director

Exact text from the filing

Effective May 2, 2023, the Board elected Dr. Veena Rao to the Board as a Class III director.

View on SEC.gov

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.